



Press Release

Uppsala, Sweden, 21 October 2002

Gyros AB expands European operations.

Gyros AB today announced the finalization of agreements with distributors B & L Systems in BeNeLux and Bucher Biotec in Switzerland to market and sell products based on the company's proprietary technology platform.

"The market response to our recent product launch, Gyrolab MALDI, has encouraged us to continue our expansion into other European regions that have a high level of pharmaceutical and biotech activity." explained Per Sjöberg, Executive Vice President Commercial Operations at Gyros AB, "Local presence in key markets is a high priority at this stage in the company's development. Our clients need efficient support and, as a company, we will rely more and more on feedback from our clients to drive the development and expansion of our product portfolio. We are extremely pleased that these well-established and well-respected distributors have shown such a strong interest in our technology.

"Gyros technology platform represents an exciting approach to solving the problems of today's modern pharmaceutical laboratories." said Paul Bucher, CEO of Bucher Biotec AG, "Establishing a business relationship with Gyros ensures that our clients are kept at the forefront of new technologies."

Hans Beijersbergen, CEO of B & L Systems, added, "We are very pleased to be in at the beginning of such an exciting concept. We see Gyrolab MALDI as just the first step in the development of this unique technology platform and look forward to handling an expanding product portfolio from Gyros."

About Gyros AB

Gyros miniaturizes and integrates laboratory applications, enabling scientists to generate more information from less sample and to improve lab performance. Using our proprietary technology platform, we increase

productivity by streamlining the many steps of conventional applications into single, nanoliter scale procedures. Optimal environments are created for each application.

A Gyrolab microlaboratory, in the form of a compact disk, can process hundreds of samples in parallel, under the control of Gyrolab Workstation. Our company will realize the full potential of the Gyros technology platform in the fields of drug discovery and diagnostics. Initial product offerings are focused towards the growing area of proteomics. Gyros has more than 90 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.

For further information, visit www.gyros.com or contact:

Maris Hartmanis, President and CEO, Gyros AB

Tel: +46 (0)18 566 330

Mobile: +46 (0)70 562 8617

Email: maris.hartmanis@gyros.com

Per Sjöberg, Executive Vice President Commercial Operations, Gyros AB

Tel: +46 (0)18 566 318

Mobile: +46 (0)70 544 4799

Email: per.sjoberg@gyros.com

Sue Cresswell, Marketing Communications

Tel: +46 (0)8 54472620

Mobile: +46 (0)70 551 9520

Email: sue.cresswell@gyros.com

About Bucher Biotec AG

Bucher Biotec AG is a Swiss distributor company representing major US and European manufacturers of scientific instruments and associated consumables for life sciences research. The company offers a broad product portfolio and is a leading supplier in the Swiss market.

For further information, visit <http://www.bucher.ch> or contact:

Title Roland Bucher, Sales Manager

Tel: +41 61 269 1111

Fax: +41 61 269 1112

email: roland.bucher@bucher.ch

About B & L Systems

B&L Systems (Biotechnology & Life Sciences) is an up-front technology supplier of products for biotechnology and life sciences in the Benelux region. Established in 1987 and based in Maarssen, The Netherlands, the company provides a wide range of instruments, reagents and consumables in the areas of cell biology, molecular biology and biochemistry. B&L Systems is well known for excellent customer service, with a considerable knowledge and expertise in biology, biochemistry and analytical chemistry, rapid order processing and delivery turnaround times and a fast response maintenance service from professionally trained service engineers, limiting costly downtime of instruments.

For further information, visit <http://www.blsystems.nl/> or contact:

Jennefer ten Broek, Marketing Manager

Tel: +31 (0)346-550556

Fax: +31 (0)346-554619

email: Jennefer.tenbroek@blsystems.nl or post@blsystems.nl

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

Gyros, Gyrolab and the Gyros logo are registered trademarks of Gyros AB.